Home / Press / CMS Hasche Sigle advises Sapiens on venture capital...

CMS Hasche Sigle advises Sapiens on venture capital financing

26/02/2013

Munich – Sapiens Steering Brain Stimulation GmbH has received EUR 7.5 million from Dutch investment group INKEF Capital as an extension of its Series A round of financing. The up-and-coming medical technology firm with offices in Eindhoven and Munich intends to use the funding to develop its products and solutions for treating Parkinson's and other brain diseases. The round of financing was opened in 2011 with an initial sum of EUR 16.5 million from Wellington Partners, Edmond de Rothschild Investment Partners, LSP and the Wellcome Trust.

CMS Hasche Sigle has been advising Sapiens on legal matters since its formation two years ago as a spin-out from Royal Philips Electronics. A team led by Stefan-Ulrich Müller also advised the company on all legal aspects of the current extension of the Series A round of financing.

Sapiens' key project is a new type of system for deep brain stimulation. The treatment relies on the delivery of electrical pulses to specific areas in the brain via implanted electrodes, with increased accuracy helping to reduce side effects. It is currently at the clinical study phase. Going forward, the method is expected to facilitate the procedures used in established stimulation therapy for healing or ameliorating Parkinson's disease, essential tremor, dystonia, obsessive compulsive disorders and epilepsy.

CMS Hasche Sigle

Stefan-Ulrich Müller, Lead Partner, Corporate
Dr Michael Wangemann, Corporate
Alexander Frauer, Corporate
Stefan Lehr, Competition

Press Contact
presse@cms-hs.com

Press releases
Press Release Sapiens, 26/02/2013
Download
PDF 99.1 kB

Related people

Portrait ofStefan-Ulrich Müller
Stefan-Ulrich Müller, M. Jur. (Oxford)
Partner
Munich
Portrait of
Dr. Michael Wangemann
Partner
Munich
Portrait ofStefan Lehr
Stefan Lehr
Partner
Frankfurt